Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 13/20 | 0.49 |
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29556779 | 1.00 | LPL (0.49) | LPLLIPGROCK1AAK1EGFR | |
| SCHEMBL29525045 | 0.88 | LPL (0.50) | LPLLIPGROCK1AAK1EGFR | |
| SCHEMBL252294 | 0.88 | LPL (0.50) | LPLLIPGROCK1AAK1EGFR | |
| SCHEMBL21364646 | 0.87 | LPL (0.46) | LPLLIPGROCK1EGFRCA1 | |
| SCHEMBL28193171 | 0.84 | LPL (0.35) | LPLLIPGROCK1 | |
| SCHEMBL31294725 | 0.84 | LPL (0.46) | LPLLIPGROCK1EGFRCA1 | |
| SCHEMBL28052008 | 0.84 | LPL (0.46) | LPLLIPGROCK1EGFRCA1 | |
| SCHEMBL2416202 | 0.83 | LPL (0.45) | LPLLIPGAAK1CA1CA2 | |
| SCHEMBL2411421 | 0.82 | LPL (0.44) | LPLLIPGAAK1EGFRCA1 | |
| SCHEMBL15096648 | 0.81 | LPL (0.44) | LPLLIPGROCK1AAK1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108689924-B | 4-amino-6- (4-substituted phenyl) -pyridine-2-carboxylic acid esters and their use as herbicides | 美国陶氏益农公司 | 2022-04-12 | — | — | CN | disclosed |
| US-10668067-B2 | Pyridine sulfonamides | AMGEN INC. (US) | 2020-06-02 | — | — | US | disclosed |
| WO-2020023393-A1 | KINASE ANTAGONISTS AND METHODS FOR MAKING AND USING THEM | BIOBLOCKS, INC. (US) | 2020-01-30 | — | — | WO | disclosed |
| US-10472356-B2 | Bicyclic ketone sulfonamide compounds | AMGEN INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-20190167682-A1 | PYRIDINE SULFONAMIDES | AMGEN INC. (US) | 2019-06-06 | — | — | US | disclosed |
| EP-3265465-B1 | BICYCLIC KETONE SULFONAMIDE COMPOUNDS | AMGEN INC (US) | 2019-04-24 | — | — | EP | disclosed |
| EP-3440938-A1 | 4-AMINO-6-(4-SUBSTITUTED-PHENYL)-PICOLINATES AND THEIR USE AS HERBICIDES | Dow AgroSciences LLC (US) | 2019-02-13 | — | — | EP | disclosed |
| EP-3440938-A1 | 4-AMINO-6-(4-SUBSTITUTED-PHENYL)-PICOLINATES AND THEIR USE AS HERBICIDES | Dow AgroSciences LLC (US) | 2019-02-13 | — | — | EP | disclosed |
| CN-105163588-B | 4-amino-6- (4-substituted phenyl) -pyridine-2-carboxylic acid esters and 6-amino-2- (4-substituted phenyl) -pyrimidine-4-carboxylic acid esters and their use as herbicides | 美国陶氏益农公司 | 2019-01-25 | — | — | CN | disclosed |
| EP-2967069-B1 | 4-AMINO-6-(4-SUBSTITUTED-PHENYL)-PICOLINATES AND 6-AMINO-2-(4-SUBSTITUTED-PHENYL)-PYRIMIDINE-4-CARBOXYLATES AND THEIR USE AS HERBICIDES | DOW AGROSCIENCES LLC (US) | 2018-10-24 | — | — | EP | disclosed |
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-11 | — | — | US | disclosed |
| EP-2508513-A1 | 2-PYRIDONE COMPOUNDS | Taisho Pharmaceutical Co., Ltd. (JP) | 2012-10-10 | — | — | EP | disclosed |
| WO-2012003283-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012003283-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| US-20110237791-A1 | 2-PYRIDONE COMPOUNDS | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-09-29 | — | — | US | disclosed |
| US-20110237791-A1 | 2-PYRIDONE COMPOUNDS | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-09-29 | — | — | US | disclosed |
| US-20110237791-A1 | 2-PYRIDONE COMPOUNDS | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-09-29 | — | — | US | disclosed |
| WO-2011068211-A1 | 2-PYRIDONE COMPOUNDS | 大正製薬株式会社 (JP) | 2011-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237791-A1 | 2-PYRIDONE COMPOUNDS | PDXK, HK1, KCNJ2 | LPL 1883/4885LIPG 3808/4885ROCK1 2097/4885 |
| US-20190167682-A1 | PYRIDINE SULFONAMIDES | TRPV1, TRPA1, TRPV5 | LPL 4322/4885LIPG 4663/4885ROCK1 3340/4885 |
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | LPL 2195/4885LIPG 1694/4885ROCK1 714/4885 |
| US-10472356-B2 | Bicyclic ketone sulfonamide compounds | TRPV1, TRPA1, KCNJ11 | LPL 4275/4885LIPG 4464/4885ROCK1 3033/4885 |
| US-10668067-B2 | Pyridine sulfonamides | TRPV1, TRPA1, TRPV5 | LPL 4322/4885LIPG 4663/4885ROCK1 3340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.